Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Mediastinal radiotherapy after chemo for newly diagnosed primary mediastinal lymphoma

Andrew Davies • 19 Jun 2020
EHA 2020
B-Cell Lymphoma Lymphoma Antibodies Rituximab
IELSG 37

Andrew Davies, BSc, BM, MRCP, PhD, of the University of Southampton, Southampton, UK, discusses the role of mediastinal radiotherapy after rituximab-containing chemotherapy regimens in patients with newly diagnosed primary mediastinal large B-cell lymphoma as evaluated in the IELSG 37 study (NCT01599559). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andrew Davies

Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023
1:11
Economic burden of CAR-T therapy from a UK perspective
Andrew Davies • 24 Apr 2023
2:40
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
Andrew Davies • 24 Apr 2023
1:44
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
Andrew Davies • 24 Apr 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals